Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 444

1.

CLL and CML sometimes meet and circulate together.

Matutes E, Polliack A.

Leuk Lymphoma. 2019 Jan 24:1-2. doi: 10.1080/10428194.2018.1564050. [Epub ahead of print] No abstract available.

PMID:
30678518
2.

Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.

Bataller A, Combalia A, Garcia-Herrera A, Estrach T, Matutes E.

Br J Haematol. 2019 Apr;185(2):205. doi: 10.1111/bjh.15744. Epub 2019 Jan 6. No abstract available.

PMID:
30613940
3.

CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.

Martín-Garcia D, Navarro A, Valdés-Mas R, Clot G, Gutiérrez-Abril J, Prieto M, Ribera-Cortada I, Woroniecka R, Rymkiewicz G, Bens S, de Leval L, Rosenwald A, Ferry JA, Hsi ED, Fu K, Delabie J, Weisenburger D, de Jong D, Climent F, O'Connor SJ, Swerdlow SH, Torrents D, Beltran S, Espinet B, González-Farré B, Veloza L, Costa D, Matutes E, Siebert R, Ott G, Quintanilla-Martinez L, Jaffe ES, López-Otín C, Salaverria I, Puente XS, Campo E, Beà S.

Blood. 2019 Feb 28;133(9):940-951. doi: 10.1182/blood-2018-07-862151. Epub 2018 Dec 11.

PMID:
30538135
4.

Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Tarín F, López-Castaño F, García-Hernández C, Beneit P, Sarmiento H, Manresa P, Alda O, Villarrubia B, Blanes M, Bernabéu J, Amorós C, Sánchez-Sánchez S, Fernández-Miñano C, De Paz F, Verdú-Belmar J, Marco P, Matutes E.

Acta Haematol. 2019;141(1):1-6. doi: 10.1159/000493568. Epub 2018 Nov 14.

5.

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.

Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N.

Haematologica. 2019 Mar;104(3):576-586. doi: 10.3324/haematol.2018.196931. Epub 2018 Sep 27.

6.

The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms.

Matutes E.

Int J Lab Hematol. 2018 May;40 Suppl 1:97-103. doi: 10.1111/ijlh.12817. Review.

PMID:
29741263
7.

Multinucleated giant myeloma cells after failure of daratumumab therapy.

Guijarro F, Rozman M, Matutes E.

Br J Haematol. 2018 May;181(4):432. doi: 10.1111/bjh.15139. Epub 2018 Feb 22. No abstract available.

PMID:
29468644
8.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T.

Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23. No abstract available.

PMID:
28643365
9.

Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.

Solé C, Martínez D, Giné E, Gonzalez-Farre B, Pérez-Galán P, Roncador G, Campo E, Matutes E, López-Guillermo A, Roué G, Martínez A.

Leuk Lymphoma. 2018 Feb;59(2):482-485. doi: 10.1080/10428194.2017.1330470. Epub 2017 Jun 2. No abstract available.

PMID:
28573896
10.

Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier.

Navarro A, Clot G, Martínez-Trillos A, Pinyol M, Jares P, González-Farré B, Martínez D, Trim N, Fernández V, Villamor N, Colomer D, Costa D, Salaverria I, Martín-Garcia D, Erber W, López C, Jayne S, Siebert R, Dyer MJS, Wiestner A, Wilson WH, Aymerich M, López-Guillermo A, Sánchez À, Campo E, Matutes E, Beà S.

Haematologica. 2017 Sep;102(9):e360-e363. doi: 10.3324/haematol.2016.160374. Epub 2017 May 18. No abstract available.

11.

Clinical features and management of non-gastrointestinal non-ocular extranodal mucosa associated lymphoid tissue (ENMALT) marginal zone lymphomas.

Matutes E, Montalban C.

Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):99-108. doi: 10.1016/j.beha.2016.07.005. Epub 2016 Nov 5. Review.

PMID:
28288723
12.

Predicting time to first treatment in early stage CLL: scores, values and comparative prognostic models.

Matutes E, Polliack A.

Leuk Lymphoma. 2017 Jul;58(7):1528-1529. doi: 10.1080/10428194.2017.1295149. Epub 2017 Mar 2. No abstract available.

PMID:
28278697
13.

Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options.

Matutes E.

Expert Rev Hematol. 2017 Mar;10(3):251-258. doi: 10.1080/17474086.2017.1284585. Epub 2017 Jan 29. Review.

PMID:
28128670
14.

The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial.

Oscier D, Else M, Matutes E, Morilla R, Strefford JC, Catovsky D.

Br J Haematol. 2016 Sep;174(5):767-75. doi: 10.1111/bjh.14132. Epub 2016 May 6.

15.

A matter of life or early death in CLL: do serum immunoglobulin levels really count?

Matutes E, Polliack A.

Leuk Lymphoma. 2016 Jul;57(7):1501-2. doi: 10.3109/10428194.2016.1170830. Epub 2016 Apr 27. No abstract available.

PMID:
27118411
16.

An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors.

Bikos V, Karypidou M, Stalika E, Baliakas P, Xochelli A, Sutton LA, Papadopoulos G, Agathangelidis A, Papadopoulou E, Davis Z, Algara P, Kanellis G, Traverse-Glehen A, Mollejo M, Anagnostopoulos A, Ponzoni M, Gonzalez D, Pospisilova S, Matutes E, Piris MA, Papadaki T, Ghia P, Rosenquist R, Oscier D, Darzentas N, Tzovaras D, Belessi C, Hadzidimitriou A, Stamatopoulos K.

Clin Cancer Res. 2016 Apr 15;22(8):2032-40. doi: 10.1158/1078-0432.CCR-15-1170. Epub 2015 Dec 8.

17.

Hairy cell leukaemia-variant: Disease features and treatment.

Matutes E, Martínez-Trillos A, Campo E.

Best Pract Res Clin Haematol. 2015 Dec;28(4):253-63. doi: 10.1016/j.beha.2015.09.002. Epub 2015 Oct 8. Review.

PMID:
26614904
18.

Recurrent pure red cell aplasia in a hepatorenal transplant recipient with chronic parvovirus B19 infection.

Rivas-Delgado A, Matutes E, Rozman M.

Br J Haematol. 2016 Feb;172(4):495. doi: 10.1111/bjh.13813. Epub 2015 Oct 12. No abstract available.

PMID:
26457576
19.

NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.

Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, Nadeu F, Enjuanes A, Clot G, Costa D, Carrio A, Villamor N, Colomer D, Martinez A, Bens S, Siebert R, Wotherspoon A, Beà S, Matutes E, Campo E.

Am J Surg Pathol. 2016 Feb;40(2):192-201. doi: 10.1097/PAS.0000000000000523.

PMID:
26426381
20.

T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more.

Matutes E, Polliack A.

Leuk Lymphoma. 2016;57(4):746-7. doi: 10.3109/10428194.2015.1081195. Epub 2015 Sep 17. No abstract available.

PMID:
26293613
21.

Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2015 Sep;26 Suppl 5:v100-7. doi: 10.1093/annonc/mdv200. Epub 2015 Aug 12. No abstract available.

PMID:
26269205
22.

Recurrent CDKN1B (p27) mutations in hairy cell leukemia.

Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T.

Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11.

23.

Is TCL1 overexpression a good or a bad player in mantle cell lymphoma?

Bea S, Matutes E.

Eur J Haematol. 2015 Dec;95(6):487-8. doi: 10.1111/ejh.12574. No abstract available.

PMID:
25919030
24.

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.

Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC.

Clin Cancer Res. 2015 Sep 15;21(18):4174-4183. doi: 10.1158/1078-0432.CCR-14-2759. Epub 2015 Mar 16.

25.

Follicular lymphoma: is peripheral blood involvement still an adverse prognostic factor in the rituximab era?

Matutes E, Seymour JF, Polliack A.

Leuk Lymphoma. 2015 Jul;56(7):1919-21. doi: 10.3109/10428194.2014.988152. Epub 2015 Jan 21. No abstract available.

PMID:
25426667
26.

Splenic marginal zone lymphoma: disease features and management.

Matutes E.

Expert Rev Hematol. 2013 Dec;6(6):735-45. doi: 10.1586/17474086.2013.845522. Epub 2013 Oct 30. Review.

PMID:
24168526
27.

Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use.

Montalban C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, Mollejo M, Matutes E, Ferreri AJ, Salar A, Rattotti S, Carpaneto A, Perez R, Bello JL, Hernandez M, Caballero D, Carbonell F, Piris MA; Splenic Marginal Zone Lymphoma Study Group (SMZLSG).

Leuk Lymphoma. 2014 Apr;55(4):929-31. doi: 10.3109/10428194.2013.818143. Epub 2013 Jul 29. No abstract available.

PMID:
23799931
28.

Annexin A1 expression in a splenic diffuse red pulp small B-cell lymphoma: report of the first case.

Mendes LS, Attygalle A, Matutes E, Wotherspoon A.

Histopathology. 2013 Oct;63(4):590-3. doi: 10.1111/his.12179. Epub 2013 Jun 24. No abstract available.

PMID:
23795986
29.

Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.

Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S, Dyer M, Matutes E, Gonzalez D, Taylor AM, Moss P, Thomas P, Oscier D, Stankovic T.

J Clin Oncol. 2012 Dec 20;30(36):4524-32. doi: 10.1200/JCO.2011.41.0852. Epub 2012 Oct 22.

PMID:
23091097
30.

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.

Oscier D, Dearden C, Eren E, Fegan C, Follows G, Hillmen P, Illidge T, Matutes E, Milligan DW, Pettitt A, Schuh A, Wimperis J; British Committee for Standards in Haematology.

Br J Haematol. 2012 Dec;159(5):541-64. doi: 10.1111/bjh.12067. Epub 2012 Oct 11. No abstract available. Erratum in: Br J Haematol. 2013 Mar;160(6):868. Dosage error in article text. Br J Haematol. 2013 Apr;161(1):154. Erem, Efrem [corrected to Eren, Efrem].

PMID:
23057493
31.

Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.

Else M, Marín-Niebla A, de la Cruz F, Batty P, Ríos E, Dearden CE, Catovsky D, Matutes E.

Br J Haematol. 2012 Nov;159(3):322-8. doi: 10.1111/bjh.12036. Epub 2012 Sep 27.

PMID:
23016878
32.

Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases.

Montalbán C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, Mollejo M, Matutes E, Ferreri A, Salar A, Rattotti S, Carpaneto A, Pérez Fernández R, Bello JL, Hernández M, Caballero D, Carbonell F, Piris MA; Splenic Marginal Zone Lymphoma Study Group.

Br J Haematol. 2012 Oct;159(2):164-71. doi: 10.1111/bjh.12011. Epub 2012 Aug 24. Erratum in: Br J Haematol. 2013 Sep;162(6):864. Iannito, Emilio [corrected to Iannitto, Emilio].

PMID:
22924582
33.

Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation.

Di Bernardo MC, Broderick P, Harris S, Dyer MJ, Matutes E, Dearden C, Catovsky D, Houlston RS.

Leukemia. 2013 Jan;27(1):255-8. doi: 10.1038/leu.2012.173. Epub 2012 Jul 2. No abstract available.

34.

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.

Matutes E, Bosanquet AG, Wade R, Richards SM, Else M, Catovsky D.

Leukemia. 2013 Feb;27(2):507-10. doi: 10.1038/leu.2012.209. Epub 2012 Jul 19. No abstract available.

35.

Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia.

Slager SL, Skibola CF, Di Bernardo MC, Conde L, Broderick P, McDonnell SK, Goldin LR, Croft N, Holroyd A, Harris S, Riby J, Serie DJ, Kay NE, Call TG, Bracci PM, Halperin E, Lanasa MC, Cunningham JM, Leis JF, Morrison VA, Spector LG, Vachon CM, Shanafelt TD, Strom SS, Camp NJ, Weinberg JB, Matutes E, Caporaso NE, Wade R, Dyer MJ, Dearden C, Cerhan JR, Catovsky D, Houlston RS.

Blood. 2012 Jul 26;120(4):843-6. doi: 10.1182/blood-2012-03-413591. Epub 2012 Jun 13.

36.

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR.

Clin Cancer Res. 2012 Aug 1;18(15):4191-200. doi: 10.1158/1078-0432.CCR-11-2936. Epub 2012 Jun 6.

37.

The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma.

Hockley SL, Else M, Morilla A, Wotherspoon A, Dearden C, Catovsky D, Gonzalez D, Matutes E.

Br J Haematol. 2012 Aug;158(3):347-54. doi: 10.1111/j.1365-2141.2012.09163.x. Epub 2012 May 18.

PMID:
22594855
38.

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P.

J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9.

PMID:
22493413
39.

Novel and emerging drugs for rarer chronic lymphoid leukaemias.

Matutes E.

Curr Cancer Drug Targets. 2012 Jun;12(5):484-504.

PMID:
22483155
40.

Mixed-phenotype acute leukemia: disease features and outcome.

Matutes E.

Clin Adv Hematol Oncol. 2011 Jul;9(7):549-50. No abstract available.

PMID:
22402463
41.

Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas.

Martinez A, Ponzoni M, Agostinelli C, Hebeda KM, Matutes E, Peccatori J, Campidelli C, Espinet B, Perea G, Acevedo A, Mehrjardi AZ, Martinez-Bernal M, Gelemur M, Zucca E, Pileri S, Campo E, López-Guillermo A, Rozman M; International Extranodal Lymphoma Study Group.

Am J Surg Pathol. 2012 Feb;36(2):296-304. doi: 10.1097/PAS.0b013e31823ea106.

PMID:
22251943
42.

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.

Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, Traverse-Glehen A, Algara P, Santoro A, Gonzalez D, Mollejo M, Dagklis A, Gangemi F, Bosler DS, Bourikas G, Anagnostopoulos A, Tsaftaris A, Iannitto E, Ponzoni M, Felman P, Berger F, Belessi C, Ghia P, Papadaki T, Dogan A, Degano M, Matutes E, Piris MA, Oscier D, Stamatopoulos K.

Leukemia. 2012 Jul;26(7):1638-46. doi: 10.1038/leu.2012.3. Epub 2012 Jan 6.

PMID:
22222599
43.

Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).

Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S, Ho A, Devereux S, Mufti GJ, Pagliuca A.

Leuk Res. 2012 Jul;36(7):857-61. doi: 10.1016/j.leukres.2011.12.004. Epub 2011 Dec 29.

PMID:
22209076
44.

Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma.

Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, Kumaran T, Ardeshna KM, Pagliuca A, Taylor GP, Fields PA.

J Clin Oncol. 2011 Dec 10;29(35):4696-701. doi: 10.1200/JCO.2011.35.5578. Epub 2011 Oct 31.

45.

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.

Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D.

Blood. 2011 Nov 24;118(22):5799-802. doi: 10.1182/blood-2011-08-372854. Epub 2011 Sep 26.

46.

ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.

Skowronska A, Austen B, Powell JE, Weston V, Oscier DG, Dyer MJ, Matutes E, Pratt G, Fegan C, Moss P, Taylor MA, Stankovic T.

Haematologica. 2012 Jan;97(1):142-6. doi: 10.3324/haematol.2011.048827. Epub 2011 Sep 20.

47.

Immunohistochemical distinction of haematogones from B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL) on bone marrow trephine biopsies: a study on 62 patients.

Al-Shieban S, Byrne E, Trivedi P, Morilla R, Matutes E, Naresh KN.

Br J Haematol. 2011 Aug;154(4):466-70. doi: 10.1111/j.1365-2141.2011.08760.x. Epub 2011 Jul 2.

PMID:
21722099
48.

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.

Else M, Dearden CE, Matutes E, Forconi F, Lauria F, Ahmad H, Kelly S, Liyanage A, Ratnayake V, Shankari J, Whalley I, Catovsky D.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:75-8. doi: 10.3109/10428194.2011.568650. Epub 2011 Apr 19.

PMID:
21504288
49.

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, Dearden CE, Richards SM, Catovsky D, Morgan GJ.

J Clin Oncol. 2011 Jun 1;29(16):2223-9. doi: 10.1200/JCO.2010.32.0838. Epub 2011 Apr 11.

PMID:
21483000
50.

High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia.

Hockley SL, Morgan GJ, Leone PE, Walker BA, Morilla A, Else M, Wotherspoon A, Dearden C, Catovsky D, Gonzalez D, Matutes E.

Leukemia. 2011 Jul;25(7):1189-92. doi: 10.1038/leu.2011.47. Epub 2011 Mar 25. No abstract available.

PMID:
21436839

Supplemental Content

Loading ...
Support Center